Menu
Your Cart

Apostle MiniGenomics Viral Total NA Isolation Kit (1536 preps), with Plates & Tip Comb Included

Apostle MiniGenomics Viral Total NA Isolation Kit (1536 preps), with Plates & Tip Comb Included
Secured Shopping
Best security features
Apostle MiniGenomics Viral Total NA Isolation Kit (1536 preps), with Plates & Tip Comb Included
  • For fast extraction and purification of viral nucleic acids from various kinds of biological samples collected in multiple transport media.  
  • Novel and original magnetic nanoparticle technology for nucleic acids isolation.   
  • Various sample types: swabs, saliva, blood.   
  • Optimized standardized protocol for viral total NA isolation in 30 min without heating.   
  • Compatible with multiple high-throughput automated nucleic acid extraction platforms.   
  • Configuration: 200uL X 1536 preps (96X16 preps,A200619P-1536).   This kit package includes both reagents and consumables (96-well deep plates and tip combs).
  • Cat #: A200619P-1536.

Documentation:

Product brochure: Apostle-COVID-19-Viral-RNA-Isolation-System.pdf

System protocol: Apostle-MiniGenomics-Viral-Total-NA-Isolation-MagTouch-protocol.pdf

Application Note: Application-Note-Apostle-Viral-RNA-Isolation-System.pdf

This links directs to an Application Note on the Apostle COVID-19 Viral RNA Extraction System, applied in the effective detection of SARS-CoV-2 in over 15 million clinical samples by our clients. 

Material Safety Data Sheet (MSDS): Apostle_MiniGenomics_Viral_Total_NA_Isolation_Fast_Kit_Material_Safety_01.pdf



Inclusion in US FDA IVD EUA - Molecular Diagnostic Tests for SARS-CoV-2

Apostle RNA extraction method is included in a US FDA EUA authorized SARS-CoV-2 molecular diagnostic test: Fulgent COVID-19 by RT-PCT Test.

$4,555.00
Tags: COVID-19
Using Apostle MiniMax cfDNA Isolation Technology a recent clinical study in 2821 myeloid or lymphoid neoplasm patients shows that liquid biopsy using targeted NGS is reliable in detecting chromosomal structural abnomalities in myeloid neoplasms. The study supports the use of liquid biopsy for early diagnosis and monitoring of patients with myeloid neoplasms. Read article